Hydrafacial Results Presentation Deck
Reconciliation of GAAP to non-GAAP measures (cont'd)
Reconciliation of research and development expense to adjusted research
and development expense
Unaudited ($ in millions)
Net sales
Research and development expense
% net sales
Adjusted to exclude the following:
Stock-based compensation expense
Accrual for annual cash incentives
Severance, restructuring and other
Adjusted research and development expense
% net sales
39
2
Note: Amounts may not sum due to rounding.
Reflects the impact of immaterial revisions to the financial statements.
Amount in the prior period adjusted for comparability purposes.
1.
2.
Three months ended June 30,
2023
$117.5
$2.9
2.5%
0.4
0.4
0.1
$2.0
1.7%
2022¹
$103.5
$2.6
2.5%
0.3
0.8
$1.6
1.5%
Six months ended June 30,
2023
$203.8
$5.2
2.6%
0.4
0.4
0.5
$4.0
1.9%
2022¹
$179.0
$4.8
2.7%
0.4
0.6
$3.8
2.1%
BEAUTYHEALTH™View entire presentation